EFFICACY OF LY2951742 IN SUBGROUPS OF PATIENTS WITH MIGRAINE OF DIFFERENT FREQUENCY

被引：0
|
作者：
Skljarevski, V. [1 ]
Martinez, J. [1 ]
Oakes, T. [1 ]
Ferguson, M. [2 ]
Tanaka, Y. [3 ]
Due, M. [4 ]
Schacht, A. [5 ]
机构：
[1] Eli Lilly & Co, Pain Team Med, Indianapolis, IN 46285 USA
[2] Eli Lilly & Co, Clin Operat, Scarborough, ON, Canada
[3] Eli Lilly & Co, RWA Capabil & Datamart, Indianapolis, IN 46285 USA
[4] Eli Lilly & Co, Global Sci Commun, Indianapolis, IN 46285 USA
[5] Eli Lilly & Co, Elanco, Indianapolis, IN 46285 USA
来源：
CEPHALALGIA | 2016年 / 36卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EHMTC-0111
引用
收藏
页码：42 / 43
页数：2
相关论文
共 50 条
  • [31] Translational Pharmacodynamics of Calcitonin Gene-Related Peptide Monoclonal Antibody LY2951742 in a Capsaicin-Induced Dermal Blood Flow Model
    Vermeersch, Steve
    Benschop, Robert J.
    Van Hecken, Anne
    Monteith, David
    Wroblewski, Victor J.
    Grayzel, David
    de Hoon, Jan
    Collins, Emily C.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2015, 354 (03): : 350 - 357
  • [32] Safety and Efficacy of Fremanezumab in Different Racial and Ethnic Subgroups of Patients with Migraine: A Pooled Analysis of Phase 3 Studies
    Charleston, Larry
    Cohen, Joshua M.
    Ning, Xiaoping
    Campos, Verena Ramirez
    Barash, Steve
    Lengil, Tamar
    Ojwang, Beryl
    Kim, Byung-Kun
    ANNALS OF NEUROLOGY, 2022, 92 : S42 - S43
  • [33] Efficacy of fremanezumab in patients with chronic and episodic migraine stratified by migraine frequency
    Nahas, Stephanie
    Ning, Xiaoping
    Campos, Verena Ramirez
    Barash, Steve
    Cohen, Joshua
    Silberstein, Stephen
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 429 : 216 - 217
  • [34] Sustained Response Outcomes from a Phase 2a, Randomized, Double-blind, Placebo-controlled Study of LY2951742, a Monoclonal Antibody to Calcitonin Generelated Peptide, for the Prevention of Migraine: A Post-hoc Analysis
    Dodick, D. W.
    Goadsby, P. J.
    Ferguson, M.
    Oakes, T.
    Tanaka, Y.
    Ni, X.
    Zhang, Q.
    Due, M.
    Skljarevski, V
    Martinez, J.
    HEADACHE, 2015, 55 : 177 - 177
  • [35] Sustained response outcomes from a phase 2a, randomized, double-blind, placebo-controlled study of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a post-hoc analysis
    Dodick, D. W.
    Goadsby, P. J.
    Skljarevski, V.
    Ferguson, M.
    Oakes, T.
    Tanaka, Y.
    Ni, X.
    Zhang, Q.
    Due, M.
    Martinez, J.
    CEPHALALGIA, 2015, 35 : 52 - 52
  • [36] Efficacy of Fremanezumab in Patients With Lower and Higher Frequency Chronic Migraine
    McAllister, Peter
    Cohen, Joshua M.
    Ning, Xiaoping
    Campos, Verena Ramirez
    Barash, Steve
    Ashina, Messoud
    NEUROLOGY, 2021, 96 (15)
  • [37] Efficacy of Fremanezumab in Patients With Moderate and Higher Frequency Episodic Migraine
    Nahas, Stephanie J.
    Ning, Xiaoping
    Cohen, Joshua M.
    Barash, Steve
    Campos, Verena Ramirez
    Silberstein, Stephen D.
    NEUROLOGY, 2021, 96 (15)
  • [38] Safety and efficacy of LY334370 IV during an acute migraine
    Granier, LA
    Vandenhende, F
    Gossen, D
    Mont-Saint-Gibert, N
    Ramadan, M
    NEUROLOGY, 2000, 54 (07) : A15 - A15
  • [39] Efficacy of Fremanezumab on Migraine Frequency and Depression in Patients with Chronic Migraine and Comorbid Moderate to Moderately Severe Depression
    Buse, D. C.
    Cohen, J. M.
    Yeung, P. P.
    Aycardi, E.
    Yang, R.
    Bibeau, K.
    Galic, M.
    Seminerio, M. J.
    Lipton, R. B.
    HEADACHE, 2018, 58 : 92 - 92
  • [40] Vestibular Migraine: Vestibular Symptom May Identify Different Subgroups
    Pereira, Cristiana B.
    Nader, Saulo N.
    Kanashiro, Aline K.
    de Carvalho, William L.
    OTOLOGY & NEUROTOLOGY, 2016, 37 (03) : 281 - 283
12345